| Assessment Status | Rapid Review Complete |
| HTA ID | 24025 |
| Drug | Risankizumab |
| Brand | Skyrizi® |
| Indication | For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional or biologic therapy. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy. |
| Assessment Process | |
| Rapid review commissioned | 02/07/2024 |
| Rapid review completed | 06/08/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations. April 2025
Reimbursement is restricted to use as a subsequent line of therapy following treatment with a lower cost biologic therapy.